Brind.

Iambic Therapeutics completes $150 million IPO on Nasdaq

1 report, 1 independent Updated Oct 14
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Iambic Therapeutics raised $150 million in an initial public offering. The startup sold nearly 9.4 million shares at $16 each and will begin trading on the Nasdaq under the ticker symbol “IAM” on Thursday. The company has received $462 million from private investors since its launch in 2019 to fund its first targeted cancer treatment.

From biopharmadive.com

Why it matters

Some supportBrind's analysis of the reports

Iambic Therapeutics is part of a growing trend of biotechnology firms using artificial intelligence to find new medicines. While the potential of AI to accelerate drugmaking is attracting significant investment, reports note that some companies in this space have struggled after going public.

From biopharmadive.com

Who's involved

  • Isomorphic LabsBritish multinational artificial intelligence company in the drug discovery space
  • AbingworthVenture capital firm that previously backed Iambic Therapeutics
  • NasdaqAmerican stock exchange where Iambic Therapeutics will begin trading
  • SECRegulatory body required for Iambic Therapeutics' IPO

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • AbingworthSpeculative

    Abingworth may realize potential liquidity and returns from its prior investment in Iambic Therapeutics.

Keep exploring

The entities involved

  • Isomorphic Labs

    British multinational artificial intelligence company

    Nothing else this week.

Coverage

Newest first; wire copies grouped